Literature DB >> 7683584

The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions.

A Gardulf1, H Björvell, R Gustafson, L Hammarström, C I Smith.   

Abstract

The life situations of 25 patients with hypogammaglobulinaemia were studied before and after the initiation of subcutaneous replacement therapy by using medical records, data registers and questionnaires (a study and a disease-specific questionnaire, the Sickness Impact Profile and the General Health Rating Index). Before treatment, the patients perceived more dysfunctions with regard to ambulation, mobility, emotional behaviour, social interaction, sleep and rest, household management, work and recreation or pastime activities compared with a Swedish reference group (P = 0.0001). A significant increase in the perceived frequency of infections was also seen in untreated patients compared with a group of healthy individuals (P = 0.0001). After 18 months of weekly subcutaneous infusions of an intramuscular gammaglobulin preparation (100 mg/kg), the patients reported a significantly increased, health-related function and improved self-rated health. A significantly higher pre-infusion IgG level was also found.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683584      PMCID: PMC1554797          DOI: 10.1111/j.1365-2249.1993.tb03380.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

Authors:  A Gardulf; L Hammarström; C I Smith
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

2.  Physical, psychologic, and social function in chronic pain patients after epidural spinal electrical stimulation.

Authors:  L E Augustinsson; L Sullivan; M Sullivan
Journal:  Spine (Phila Pa 1976)       Date:  1986-03       Impact factor: 3.468

3.  Home intravenous immunoglobulin therapy by self-administration.

Authors:  E R Ashida; A Saxon
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

4.  Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases.

Authors:  H D Ochs; S H Fischer; M L Lee; E S Delson; H S Kingdon; R J Wedgwood
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

5.  Predicting changes in perceived health status.

Authors:  M S Goldstein; J M Siegel; R Boyer
Journal:  Am J Public Health       Date:  1984-06       Impact factor: 9.308

6.  The Sickness Impact Profile: development and final revision of a health status measure.

Authors:  M Bergner; R A Bobbitt; W B Carter; B S Gilson
Journal:  Med Care       Date:  1981-08       Impact factor: 2.983

7.  Perceived health and mortality: a nine-year follow-up of the human population laboratory cohort.

Authors:  G A Kaplan; T Camacho
Journal:  Am J Epidemiol       Date:  1983-03       Impact factor: 4.897

8.  Intravenous immune serum globulin in immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

9.  Measuring health in rheumatic disorders by means of a Swedish version of the sickness impact profile. Results from a population study.

Authors:  M Sullivan; M Ahlmén; B Archenholtz; G Svensson
Journal:  Scand J Rheumatol       Date:  1986       Impact factor: 3.641

10.  1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.

Authors:  J Björkander; C Wadsworth; L A Hanson
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

View more
  28 in total

1.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

2.  Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL.

Authors:  G H Jörgensen; A Gardulf; M I Sigurdsson; S Arnlaugsson; L Hammarström; B R Ludviksson
Journal:  Qual Life Res       Date:  2014-03       Impact factor: 4.147

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  An immune globulin intravenous (human), 10% liquid privigen: for the treatment of primary immunodeficiency diseases.

Authors: 
Journal:  P T       Date:  2009-06

Review 5.  X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase.

Authors:  C I Smith; C M Bäckesjö; A Berglöf; L J Brandén; T Islam; P T Mattsson; A J Mohamed; S Müller; B Nore; M Vihinen
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Immune globulin intravenous (human), 5% liquid gammaplex: for replacement therapy of primary humoral immunodeficiency.

Authors: 
Journal:  P T       Date:  2011-06

Review 7.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

Review 8.  Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors:  Richard L Wasserman
Journal:  J Clin Immunol       Date:  2012-07-25       Impact factor: 8.317

9.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

10.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.